sugemalimab + capecitabine + oxaliplatin

Sugemalimab + capecitabine + oxaliplatin is a combination therapy consisting of **sugemalimab**, a fully human IgG4 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), with **capecitabine** and **oxaliplatin**, two standard chemotherapeutic agents, commonly known together as CAPOX. Sugemalimab acts as an immune checkpoint inhibitor by blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby promoting T-cell-mediated immune responses against tumors. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), inhibiting DNA synthesis, while oxaliplatin is a platinum-based agent causing DNA crosslinking and apoptosis. The combination is evaluated and used as a first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a PD-L1 combined positive score (CPS) ≥5.

Other names

CAPOX